Management of Myotonic Dystrophy Patients with Respiratory Failure

Introduction to Myotonic Dystrophy and Respiratory Complications

Myotonic dystrophy patients have compromised respiratory function due to progressive weakness of respiratory muscles, leading to hypoventilation, sleep-disordered breathing, and reduced ability to clear secretions, according to the British Thoracic Society guidelines 1
Respiratory complications are a major cause of morbidity and the second most frequent cause of death in muscular dystrophy patients, with patients showing increased sensitivity to central nervous system depressants, including benzodiazepines like lorazepam 1

Respiratory muscle weakness and paralysis are primarily caused by neuromuscular disorders, neurological diseases, and genetic conditions, leading to decreased tidal volumes and ineffective cough, which can progress to respiratory failure, as stated by the European Respiratory Review and the American Journal of Respiratory and Critical Care Medicine 2, 3
Diaphragmatic weakness is particularly critical and may manifest as orthopnea or paradoxical breathing, according to the American Journal of Respiratory and Critical Care Medicine 3
Decreased maximum inspiratory and expiratory pressures (MIP and MEP) are associated with respiratory muscle weakness, as stated by the European Respiratory Review and the American Journal of Respiratory and Critical Care Medicine 2, 3
Malnutrition can worsen respiratory muscle weakness, and individuals with a family history of neuromuscular diseases have a higher probability of developing the disease, with the risk depending on the specific type and pattern of inheritance, as noted by the American Heart Association 4

Patients with myotonic dystrophy may not display typical signs of respiratory distress despite significant compromise, and even with normal or near-normal vital capacity measurements, patients may have chronic ventilatory failure, highlighting the need for close monitoring, as recommended by the British Thoracic Society guidelines 1
Patients with respiratory muscle weakness may experience nocturnal hypoventilation, morning headaches, daytime fatigue, orthopnea, and decreased vital capacity with a significant drop (>30%) when supine, as reported by the American Journal of Respiratory and Critical Care Medicine 3
Ineffective cough, recurrent respiratory infections, sleep-disordered breathing, and hypercapnia are common complications, according to the American Journal of Respiratory and Critical Care Medicine 3
Genetic testing is essential for definitive diagnosis, genetic counseling, and presymptomatic diagnosis, as recommended by the American College of Cardiology 4 and the American College of Medical Genetics 5

Non-invasive ventilation, airway clearance techniques, and assisted cough are used to manage respiratory function, as stated by the European Respiratory Society 1
Early intervention with ACE inhibitors or ARBs, beta-blockers, and mineralocorticoid receptor antagonists are used to manage cardiac function, according to the American Heart Association 4
Corticosteroids are the standard of care for DMD, slowing the rate of decline in muscle function, prolonging ambulation, and delaying respiratory decline, as reported by the American Academy of Neurology 1
For patients requiring anxiolysis or sedation, consider non-pharmacological approaches first, and if medication is necessary, consult with a specialist respiratory team with experience in managing neuromuscular disorders, as recommended by the British Thoracic Society guidelines 1
If lorazepam is administered, it should be done in a setting with continuous respiratory monitoring, starting with the lowest possible dose (less than 1mg), with close monitoring of CO2 levels, and having non-invasive ventilation immediately available, according to the British Thoracic Society guidelines 1

Cardiomyopathy is the leading cause of death in DMD patients, affecting the cardiac muscle progressively, and respiratory failure can trigger cardiac arrhythmias and exacerbate cardiac failure, as reported by the American Heart Association 4 and the British Thoracic Society 1
Conduction defects and arrhythmias are common in EDMD, LGMD1B, and myotonic dystrophy, with risk of tachyarrhythmias increasing with ventricular dysfunction, according to the American Heart Association 4
Echocardiography has limitations in DMD patients, while cardiac MRI with late gadolinium enhancement can detect early myocardial damage, as stated by the American Heart Association 6

The current median life expectancy in the UK is 29-30 years with multidisciplinary care, according to the British Thoracic Society 1
Variable progression based on repeat expansion size, anticipation phenomenon, and respiratory complications are primary causes of death, as stated by the American Heart Association 4 and the American College of Medical Genetics 7
Respiratory complications are a major cause of morbidity, unplanned hospitalizations, and the second most common cause of death in DMD patients, after cardiac failure, due to weakness of inspiratory muscles, leading to hypoventilation and sleep disorders, as reported by the British Thoracic Society 1